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A B S T R A C T   
Introduction: Limited data is available on the rates of bleeding and thromboembolic events for patients under-
going low bleeding risk procedures while taking direct oral anticoagulants (DOAC). 
Methods: Adults taking DOAC in the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) database 
who underwent a low bleeding risk procedure between May 2015 and Sep 2019 were included. Thirty-day 
bleeding (of any severity), thromboembolic events, and death were compared between DOAC temporarily 
interrupted and continued uninterrupted groups. Adverse event rates were compared using an inverse proba-
bility weighting propensity score. 
Results: There were 820 patients who underwent 1412 low risk procedures. DOAC therapy was temporarily 
interrupted in 371 (45.2%) patients (601 [42.6%] procedures) and continued uninterrupted in 449 (54.8%) 
patients (811 [57.4%] procedures). DOAC patients with temporary interruptions were more likely to have 
diabetes, prior stroke or TIA, prior bleeding, higher CHA2DS2-VASc, and higher modified HAS-BLED scores. 
DOAC interruption was common for gastrointestinal endoscopy, electrophysiology device implantation, and 
cardiac catheterization while it was less common for cardioversion, dermatologic procedures, and subcutaneous 
injection. After propensity score adjustment, bleeding risk was lower in the DOAC temporary interruption group 
(OR 0.62, 95% CI 0.41–0.95) as compared to the group with continuous DOAC use. Rates of thromboembolic 
events and death did not differ significantly between the two groups. 
Conclusions: DOAC-treated patients undergoing low bleeding risk procedures may experience lower rates of 
bleeding when DOAC is temporarily interrupted. Prospective studies focused on low bleeding risk procedures are 
needed to identify the safety DOAC management strategy.   
1. Introduction 
Atrial fibrillation (AF) and venous thromboembolism (VTE) are 
major health problems in the United States with an estimated 1.2 million 
cases of AF in 2010 and 1 million VTE events occurring in 2014 alone 
[1]. Anticoagulation used in these patients to prevent thromboembolic 
complications also increases the risk of bleeding [2]. Since 2009, the 
direct oral anticoagulants (DOAC) have gained prominence and are now 
increasingly used as compared to warfarin [3]. 
In preparation for surgical or invasive procedures, patients often 
require a temporary interruption of the anticoagulant to reduce peri- 
procedural bleeding risk [4]. For certain lower bleeding risk proced-
ures, such as pacemaker implantation or ablation of atrial fibrillation, 
randomized trial data in both warfarin- and DOAC-treated patients 
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suggests safety and efficacy when the anticoagulant is continued unin-
terrupted [5–11]. While peri-procedural anticoagulation management 
for electrophysiology (EP) procedures has been fairly well studied, 
limited data is available to compare temporary interruption versus 
routine continuation of DOAC medications for other low bleeding risk 
procedures. We aimed to describe rates of bleeding and thromboembolic 
events for patients undergoing low bleeding risk procedures while tak-
ing DOAC medications. 
2. Methods 
Patients taking DOAC therapy were identified from four hospitals 
participating in the Michigan Anticoagulation Quality Improvement 
Initiative (MAQI2). MAQI2 is a Blue Cross Blue Shield of Michigan/Blue 
Care Network (BCBSM/BCN)-funded collaborative of hospitals- or group 
practice-affiliated anticoagulation services across the state of Michigan. 
Beginning in 2015, patients initiated on DOAC therapy at a participating 
MAQI2 center were eligible for enrollment in the MAQI2 database. Pa-
tients were randomly selected monthly for enrollment into the registry. 
During the study period, MAQI2 had no impact on anticoagulant man-
agement decisions, which were made by the primary providers. Data 
abstractors undergo standardized training and participating sites un-
dergo regular audits to ensure that abstracted data is accurate and 
concordant with pre-set clinical definitions. Major clinical events 
(including stroke, systemic embolism and major bleeding events) un-
dergo audit by the coordinating center. Use of the MAQI2 registry is 
approved with a waiver of informed consent by the Institutional Review 
Boards at the University of Michigan (coordinating center) and at each 
participating site. [12–14] 
2.1. Patient selection 
From the MAQI2 DOAC registry, we identified adult patients taking 
DOAC medications at the four participating sites who underwent a low 
bleeding risk procedure between May 2015 to September 2019. Low 
bleeding risk procedures included: biopsy (e.g. bone marrow, thyroid, 
endometrial), bronchoscopy, cardiac ablation, cardiac catheterization, 
cardioversion, cutaneous incision and drainage, cystoscopy, dental 
procedure, dermatologic procedure, electrophysiology device implan-
tation, gastrointestinal (GI) endoscopy, ophthalmologic procedure, 
peripherally inserted central catheter placement, port placement/ 
removal, subcutaneous injection, and other surgery/procedure lasting 
<1 h (procedures not categorized into any of the previous groups with 
duration less than 1 h). This criteria was initially developed based on 
similar criteria used in the BRIDGE (Perioperative Bridging Anti-
coagulation in Patients with Atrial Fibrillation) trial [15]. 
Patients on heparin or low molecular weight heparin (LMWH) 
bridging, and those undergoing moderate- or high-bleeding risk pro-
cedure were excluded. 
2.2. Data collection 
Since patients may undergo multiple procedures with different peri- 
procedural anticoagulation management for each procedure, analysis 
Fig. 1. Standardized difference plot before and after inverse probability weighting.  
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was based on the procedure- rather than the patient-level. Procedures 
were categorized based on DOAC management, namely if DOAC medi-
cations were temporarily interrupted or continued uninterrupted. This 
information is obtained by data abstractors during chart review. The 
decision of peri-procedural interruption or continuation was made by 
the primary providers, typically without input from the anticoagulation 
clinic or research team. Therefore, no details about reasons for DOAC 
interruption or continuation are available for analysis. 
Determination of continuation or interruption of DOAC was made by 
reviewing all available provider notes in the electronic medical record. 
We defined interruption as at least one missed dose of DOAC prior to 
procedure. If periprocedural anticoagulation management was not clear 
after thorough chart review, the DOAC status around the procedure was 
recorded as “unknown”. The procedures for which DOAC continuation 
or interruption was unknown were excluded. Of the 2259 total pro-
cedures in the database, 239 had unknown DOAC continuation or 
interruption status which were excluded. Of the 2020 total procedures 
with known DOAC status 1412 were low-risk procedures. 
2.3. Outcomes 
Thirty-day bleeding events, thromboembolic events, and death were 
compared between the interrupted and uninterrupted groups. All events 
were abstracted from the medical chart by trained abstractors using pre- 
specified data forms and definitions. Bleeding was characterized as 
major, clinically relevant non-major (CRNM), or minor according to the 
International Society of Thrombosis and Hemostasis (ISTH) consensus 
definitions [16,17]. Bleeding events of any severity (major, minor and 
CRNM) were grouped and reported as ‘any bleeding.’ Stroke and sys-
temic embolism were defined according to physician diagnosis or 
discharge diagnosis and abstracted into the registry. 
2.4. Statistical analysis 
For baseline group comparisons, standardized differences were used 
(Fig. 1) Adverse events were compared by Poisson test and reported as 
95% confidence interval (CI) of difference. To adjust for measured po-
tential confounders, we used an inverse probability weighted regression 
adjustment approach. A propensity model with clinical and de-
mographic elements listed in Table 1 and Fig. 1 was used to calculate 
inverse probability weight in two groups, namely diabetes, prior stroke 
or TIA, renal disease, anemia, prior bleeding event, drug use (aspirin, 
clopidogrel, prasugrel, ticagrelor or NSAIDs) and procedure type, and 
modified HAS-BLED score [18] [without labile INR (International 
Normalized Ratio)]. A logistic model was preformed based on inverse 
probability weights, to model outcomes adjusted by significant clinical 
and demographic elements. Results were reported as odds ratio with 
their 95% confidence intervals. Standardized weights before adjustment 
and after inverse probability weighting are shown in Fig. 1. A two-sided 
P < 0.05 was considered statistically significant for all analyses. Ana-
lyses were performed with statistical software SAS version 9.4 (Cary, 
NC) and R version 3.3.1. 
3. Results 
There were 820 patients who underwent 1412 low risk procedures. 
Atrial fibrillation was indication for anticoagulation for the majority: 
1069 AF, 278 VTE, and 1 for AF and VTE. DOAC therapy was tempo-
rarily interrupted in 371 (45.2%) patients (601 [42.6%] procedures) and 
continued in 449 (54.8%) patients (811 [57.4%] procedures). Apixaban, 
rivaroxaban, dabigatran and rivaroxaban were the DOAC medications 
included. 
As shown in Table 1, procedures where a patient’s DOAC was 
temporarily interrupted were more likely to occur in patients with 
Table 1 
Demographic comparison between DOAC temporarily interrupted and continued uninterrupted groups.  
Demographics DOAC temporarily interrupted 
N = 371 
DOAC continued uninterrupted 
N = 449 
Standardized difference 
Unweighted Unweighted 
Age 69.9 ± 12.6 69.7 ± 12.8 0.0166 0.0166 
Male Gender 206 (55.5%) 255 (56.8%) − 0.0543 − 0.0543 
Hypertension 284 (76.6%) 334 (74.4%) 0.0936 0.0936 
Heart Failure 84 (22.6%) 94 (20.9%) 0.0139 0.0139 
Diabetes Mellitus 112 (30.2%) 101 (22.5%) − 0.0650 − 0.0650 
Prior Stroke or TIA 64 (17.3%) 43 (9.6%) − 0.2129 − 0.2129 
CAD, PAD or Aortic plaque 122 (32.9%) 129 (28.7%) 0.1555 0.1555 
Chronic Liver Disease or Cirrhosis 20 (5.4%) 22 (4.9%) − 0.0108 − 0.0108 
Chronic Renal Insufficiency 65 (17.5%) 56 (12.5%) − 0.1692 − 0.1692 
Heavy Alcohol Use 28 (7.6%) 31 (6.9%) 0.0516 0.0516 
Malignancy 115 (31.0%) 138 (30.7%) − 0.0762 − 0.0762 
Thrombocytopeniaa 44 (11.9%) 54 (12.0%) − 0.0510 − 0.0510 
Severe Thrombocytopeniab 2 (0.54%) 4 (0.89%) 0.0220 0.0220 
Anemiac 150 (40.4%) 112 (25.1%) − 0.2365 − 0.2365 
Prior Bleeding Event 186 (50.1%) 150 (33.4%) − 0.1955 − 0.1955 
History of Falls 47 (12.7%) 44 (9.8%) 0.1174 0.1174 
Bleeding diathesis 0 2 (0.45%) – – 
Hypercoagulable state 5 (1.4%) 6 (1.3%) 0.0478 0.0478 
Drugsd 130 (35.0%) 129 (28.7%) − 0.2234 − 0.2234 
CHA2DS2-VASc score 3.5 ± 1.9 3.2 ± 1.8 0.1895 0.1895 
Modified HAS-BLED Score 2.8 ± 1.4 2.4 ± 1.2 0.3271 0.3271 
Apixaban 258 (69.6%) 289 (64.4%) 0.1253 0.1253 
Rivaroxaban 107 (28.8%) 154 (34.3%) − 0.1256 − 0.1256 
Dabigatran 6 (1.6%) 5 (1.1%) 0.0081 0.0081 
Edoxaban 0 1 (0.22%) – – 
Abbreviations: TIA = transient ischemic attack; CAD = coronary artery disease; PAD = peripheral arterial disease; NSAIDs = nonsteroidal anti-inflammatory drugs; 
CHA2DS2-VASc = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex 
category; HAS-BLED = hypertension, abnormal renal and liver function, stroke, bleeding, labile INR (excluded), elderly, drugs or alcohol. 
a Platelet count of <150,000/L. 
b Platelet count of <50,000/L. 
c Hemoglobin <13 g/dL for Men and < 12 g/dL for Women. 
d Use of aspirin, clopidogrel, prasugrel, ticagrelor or NSAIDs. 
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diabetes (30.2% vs 22.5%), prior stroke or transient ischemic attack 
(17.3% vs 9.6%), anemia (40.4% vs 25.1%), prior bleeding (50.1% vs 
33.4%) and higher modified HAS-BLED scores (2.8 ± 1.4 vs 2.4 ± 1.2). 
Patients with procedures where DOAC therapy was temporarily inter-
rupted also had higher CHA2DS2-VASc scores (3.5 ± 1.9 vs 3.2 ± 1.8). 
Use of different DOAC agents (apixaban, rivaroxaban, dabigatran and 
edoxaban) was similar in both groups.: apixaban 69.6% vs 64.4% (p 
0.12), rivaroxaban 28.8% vs 34.3% (p 0.09), dabigatran 1.6% vs 1.1% (p 
0.56) and edoxaban 0% vs 0.22% respectively. 
Procedures for which DOAC therapy was most likely to be tempo-
rarily interrupted included gastrointestinal (GI) endoscopy (223/263, 
84.5%), electrophysiology (EP) device implantation (42/53, 79.2%) and 
cardiac catheterization (83/105, 79%). Procedures where DOAC was 
most likely to be continued uninterrupted included cardioversion (304/ 
313, 97.1%), dermatologic procedures (112/129, 86.8%) and subcu-
taneous injection (67/80, 83.8%) (Table 2). 
A small proportion were on low-dose DOAC (defined as rivaroxaban 
10 mg daily or apixaban 2.5 mg twice daily). Out of total 820 patients 64 
(7.8%) were taking low-dose DOAC medication; the corresponding 
numbers in the DOAC temporarily interrupted group were 29/371 
(7.8%) and in the DOAC continued uninterrupted group 35/449 (7.8%). 
At the procedure level also a small percentage were on low-dose DOAC: 
105/1412 (7.4%) for all procedures, 50/601 (8.3%) for procedures were 
DOAC was temporarily interrupted and 55/811 (6.8%) when DOAC was 
continued uninterrupted (Table 3). 
Unadjusted analysis showed that procedures where a patient 
temporarily interrupted DOAC therapy experienced more 30-day 
bleeding events and higher incidence of death without a statistically 
significant difference in thromboembolic events as compared to pro-
cedures with continued DOAC use (Table 4). In adjusted analyses, the 
risk of bleeding decreased when DOAC therapy was temporarily inter-
rupted (OR 0.59, 95% CI 0.39–0.91), while risk of thromboembolic 
events (OR 1.31, 95% CI 0.26–6.85) and death (OR 0.29, 95% CI 
0.04–2.26) showed no statistically significant difference in the two 
treatment groups. (Fig. 2). 
4. Discussion 
In this retrospective cohort study of peri-procedural DOAC man-
agement in low bleeding risk procedures, temporary interruption of 
DOAC medications compared to uninterrupted DOAC therapy showed 
slightly decreased risk of any bleeding. 
The largest study of head-to-head comparison of peri-procedural 
DOAC interruption vs continuation is the BRUISE CONTOL-2 which 
studied patients undergoing cardiac electrophysiology procedures [11]. 
Their rates of bleeding (hematoma) of around 5% for all hematomas and 
2% for device pocket hematoma in both groups were lower than ours 
(9% and 6%). A sub-study of the ARISTOTLE trial (apixaban vs. warfarin 
for atrial fibrillation) reported on perioperative bleeding when apixaban 
was continued uninterrupted. The most common procedures included 
were somewhat similar to those we studied. Major bleeding occurred in 
28 of 1752 (1.6%) of patients operated on when apixaban was continued 
uninterrupted [19]. These both differ somewhat from the findings in our 
study, which demonstrated lower bleeding risk when DOAC therapy is 
temporarily interrupted. Both these studies focused on EP procedures for 
atrial fibrillation whereas we included a wide variety of low bleeding 
risk procedures (also including EP procedures) that is likely responsible 
for the differing results. Moreover, due to unselected population of 
DOAC-treated patients, and the retrospective data collection we likely 
Table 2 
DOAC interruption and continuation for each procedure.  




N (%) Bleeding 
N (%) 












or loop recorder  
53 42 
(79.20) 
7 (16.67) 11 
(20.80) 
1 (9.09) 
Cardiac catheterization  105 83 
(79.00) 
6 (7.23) 22 
(21.00) 
4 (18.18) 
Cardiac Ablation  138 85 
(61.60) 
9 (10.59) 53 
(38.40) 
3 (5.66) 
Dental surgery or other 
dental procedure  
24 14 
(58.33) 
1 (7.14) 10 
(41.67) 
2 (20) 









2 (40) 5 
(50.00) 
0 





Any other surgery or 
procedure lasting less 
than 1 h  
154 74 
(48.10) 
4 (5.41) 80 
(51.90) 
6 (7.5) 





1 (11.11) 10 
(52.63) 
1 (10) 



































Cardioversion  313 9 (2.9) 1 (11.11) 304 
(97.10) 
14 (4.61)  
Table 3 
Low dose DOAC use.   




Patient level (number 
of patients) 
820 371 449 
On Low-dose DOACa 64 
(7.8%) 




1412 601 811 
On Low-dose DOACa 105 
(7.4%) 
50 (8.3%) 55 (6.8%)  
a Rivaroxaban 10 mg daily or apixaban 2.5 mg twice daily. 
Table 4 
Unadjusted outcomes.  




N = 601 
DOAC continued 
uninterrupted 
N = 811 
p- 
Value 
Primary    
Any bleeding events 56 (9.3%) 51 (6.3%)  0.03 
Major bleed 9 (1.50%) 4 (0.49%)  0.05 
Minor bleed 47 (7.82%) 47 (5.80%)  0.13 
CRNM bleeda 19 (3.16%) 15 (1.85%)  0.11 
Any thromboembolic 
events 
3 (0.50%) 4 (0.49%)  1 
Secondary    
Death due to any cause 5 (0.83%) 2 (0.25%)  0.14 
CRNM = clinically relevant non-major. 
a minor bleeds that resulted in ED visits/hospitalizations. 
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had a more heterogeneous patient population which also may explain 
why our findings are different. 
In our study, DOAC therapy was most likely to be temporarily 
interrupted for GI endoscopy, EP device implantation, and cardiac 
catheterization procedures. Risk of bleeding from a potential biopsy 
during endoscopy and use of heparin during cardiac catheterization 
likely explain the inclination to interrupt DOAC. However, temporary 
interruption of DOAC therapy for EP device procedures is somewhat 
surprising given the robust evidence in favor of uninterrupted continu-
ation [5,7–11]. One potential explanation is that with limited DOAC 
experience and lack of trust or availability in DOAC-specific reversal 
agents, many clinicians will prefer to stop DOAC therapy and instead 
initiate heparin. Some patients take low-dose direct oral anticoagulants 
for long-term venous thromboembolism prevention and providers might 
be more comfortable continuing this level of anticoagulation versus full 
therapeutic dose surrounding low-risk procedures. We found that a 
small percentage and similar number were on low-dose DOAC in both 
groups at both patient and procedure level, hence it is not likely to be 
related to the outcomes. 
The recent PAUSE study (Perioperative Anticoagulation Use for 
Surgery Evaluation) demonstrated relative safety and efficacy for a 
simple perioperative DOAC interruption and resumption protocol for 
patients undergoing elective procedures, which span the bleeding risk 
spectrum from low to high [20]. Unlike this study we did not include 
high bleeding risk procedures in our analysis. However, the low bleeding 
risk procedures in PAUSE included common gastrointestinal procedures 
(e.g., colonoscopy), cardiac procedures (e.g., permanent pacemaker 
implantation or battery change, coronary artery angiography), dental 
procedures, skin procedures, and eye procedures. These low-risk pro-
cedures largely overlapped with those included in our study. Given our 
observation that routine continuation of DOAC medications (compared 
to temporary interruption) was associated with increased bleeding risk, 
a standardized approach to temporary interruption of DOAC medica-
tions when patients undergo low bleeding risk procedures may be useful. 
This warrants further investigation in a prospective study. 
An important strength of our study is that the MAQI2 cohort com-
prises contemporary real-world patients receiving care in a variety of 
anticoagulation clinics in both suburban and urban settings, and 
therefore represents typical patients on anticoagulation in the commu-
nity. Unlike administrative databases relying on diagnostic and billing 
codes, our data is manually abstracted by trained personnel and inde-
pendently audited to verify accurate assessment of comorbidities and 
events. MAQI2 auditing ensures highly reliable data abstraction with few 
patients lost to follow up. The study also has several limitations. As with 
all retrospective studies, the effect of unmeasured confounding cannot 
be ruled out even after the use of propensity score methods. Addition-
ally, some adverse outcomes may not have been captured by our reg-
istry, especially if patients presented to a different health care system. 
However, if any adverse event was noted in their medical chart, even in 
follow up with a primary care provider or other specialist, those events 
would be identified and abstracted into the MAQI2 registry. 
5. Conclusions 
DOAC-treated patients undergoing low bleeding risk procedures may 
have increased bleeding risk when DOAC therapy is continued unin-
terrupted as compared to when it is temporarily interrupted. 
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